NCT06968988View on ClinicalTrials.gov

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 12, 2026

Study Completion Date

March 31, 2031

Conditions
Metastatic Soft-tissue Sarcoma
Interventions
DRUG

Zanzalintinib

Zanzalintinib will be supplied by Exelixis, Inc.

DRUG

Ipilimumab

Ipilimumab will be commercially sourced.

DRUG

Nivolumab

Nivolumab will be commercially sourced.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT06968988 - Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter